TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - TScan Therapeutics reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.32 per share a year ago, representing an earnings surprise of 7.14% [1] - The company posted revenues of $2.17 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 34.43%, compared to revenues of $0.57 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates three times [2] Stock Performance - TScan Therapeutics shares have declined approximately 50.7% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $1.62 million, and for the current fiscal year, it is -$1.15 on revenues of $10.97 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TScan's stock performance [5]